BR112018002520A2 - Agonistas de tlr4 e composições dos mesmos e seuuso no tratamento de câncer - Google Patents
Agonistas de tlr4 e composições dos mesmos e seuuso no tratamento de câncerInfo
- Publication number
- BR112018002520A2 BR112018002520A2 BR112018002520A BR112018002520A BR112018002520A2 BR 112018002520 A2 BR112018002520 A2 BR 112018002520A2 BR 112018002520 A BR112018002520 A BR 112018002520A BR 112018002520 A BR112018002520 A BR 112018002520A BR 112018002520 A2 BR112018002520 A2 BR 112018002520A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- same
- cancer treatment
- tlr4 agonists
- tlr4
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
trata-se de um agonista de tlr4 isoladamente ou em combinação com um agente anticâncer e composições farmacêuticas do mesmo, usos do mesmo e métodos de tratamento que compreende administrar a dita composição ou combinação, que inclui usos em câncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562201912P | 2015-08-06 | 2015-08-06 | |
PCT/IB2016/053290 WO2017021792A1 (en) | 2015-08-06 | 2016-06-03 | Tlr4 agonists and compositions thereof and their use in the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018002520A2 true BR112018002520A2 (pt) | 2018-09-18 |
Family
ID=56121139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018002520A BR112018002520A2 (pt) | 2015-08-06 | 2016-06-03 | Agonistas de tlr4 e composições dos mesmos e seuuso no tratamento de câncer |
Country Status (10)
Country | Link |
---|---|
US (1) | US10765690B2 (pt) |
EP (1) | EP3331565A1 (pt) |
JP (1) | JP2018522053A (pt) |
KR (1) | KR20180032642A (pt) |
CN (1) | CN108136024A (pt) |
AU (1) | AU2016303387B2 (pt) |
BR (1) | BR112018002520A2 (pt) |
CA (1) | CA2994790A1 (pt) |
RU (1) | RU2018107930A (pt) |
WO (1) | WO2017021792A1 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11433131B2 (en) | 2017-05-11 | 2022-09-06 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (SNAs) |
MX2020008417A (es) | 2018-02-12 | 2020-11-11 | Inimmune Corp | Ligandos de receptores de tipo toll. |
WO2020007760A1 (en) * | 2018-07-03 | 2020-01-09 | Glaxosmithkline Intellectual Property Development Limited | Tlr4 compounds or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions or formulations, methods of preparation, treatment or uses |
WO2020031087A1 (en) * | 2018-08-06 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
AU2021380287A1 (en) * | 2020-11-11 | 2023-06-22 | Daiichi Sankyo Company, Limited | Novel aminoalkyl glucosaminide 4-phosphate derivative |
CN117018195A (zh) * | 2023-08-04 | 2023-11-10 | 中国人民解放军海军军医大学 | 小分子化合物或组合在制备启动肝脏原位再生药物中的应用 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
KR100829674B1 (ko) | 2000-05-19 | 2008-05-16 | 코릭사 코포레이션 | 단당류 또는 이당류계 화합물을 이용한 전염성 및 다른질병의 예방 및 치료 방법 |
ATE321063T1 (de) | 2000-08-04 | 2006-04-15 | Corixa Corp | Neue immunoeffectorverbindungen |
US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
US6525028B1 (en) | 2002-02-04 | 2003-02-25 | Corixa Corporation | Immunoeffector compounds |
US7030094B2 (en) * | 2002-02-04 | 2006-04-18 | Corixa Corporation | Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and QS-21 |
US6911434B2 (en) | 2002-02-04 | 2005-06-28 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
US7288640B2 (en) | 2002-07-08 | 2007-10-30 | Corixa Corporation | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor |
US7960522B2 (en) | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
WO2005040229A2 (en) | 2003-10-24 | 2005-05-06 | Avidia, Inc. | Ldl receptor class a and egf domain monomers and multimers |
ES2629337T3 (es) * | 2009-02-09 | 2017-08-08 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos |
NO2575876T3 (pt) | 2010-05-26 | 2018-05-05 | ||
GB201101331D0 (en) * | 2011-01-26 | 2011-03-09 | Glaxosmithkline Biolog Sa | Compositions and uses |
US20120321694A1 (en) | 2010-10-27 | 2012-12-20 | Daniel Larocque | Compositions and uses |
BR112015025709A2 (pt) * | 2013-04-18 | 2017-07-18 | Immune Design Corp | monoterapia com gla para uso em tratamento de câncer |
-
2016
- 2016-06-03 JP JP2018506137A patent/JP2018522053A/ja active Pending
- 2016-06-03 KR KR1020187005943A patent/KR20180032642A/ko unknown
- 2016-06-03 EP EP16729070.9A patent/EP3331565A1/en not_active Withdrawn
- 2016-06-03 AU AU2016303387A patent/AU2016303387B2/en not_active Ceased
- 2016-06-03 CA CA2994790A patent/CA2994790A1/en not_active Abandoned
- 2016-06-03 US US15/749,854 patent/US10765690B2/en active Active
- 2016-06-03 RU RU2018107930A patent/RU2018107930A/ru not_active Application Discontinuation
- 2016-06-03 CN CN201680058161.3A patent/CN108136024A/zh active Pending
- 2016-06-03 BR BR112018002520A patent/BR112018002520A2/pt not_active Application Discontinuation
- 2016-06-03 WO PCT/IB2016/053290 patent/WO2017021792A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
US20180221399A1 (en) | 2018-08-09 |
CA2994790A1 (en) | 2017-02-09 |
RU2018107930A3 (pt) | 2019-12-06 |
CN108136024A (zh) | 2018-06-08 |
KR20180032642A (ko) | 2018-03-30 |
WO2017021792A1 (en) | 2017-02-09 |
EP3331565A1 (en) | 2018-06-13 |
RU2018107930A (ru) | 2019-09-06 |
AU2016303387A1 (en) | 2018-02-22 |
US10765690B2 (en) | 2020-09-08 |
JP2018522053A (ja) | 2018-08-09 |
AU2016303387B2 (en) | 2019-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018002520A2 (pt) | Agonistas de tlr4 e composições dos mesmos e seuuso no tratamento de câncer | |
BR112018010418A2 (pt) | complexo de agente quimioterápico em microbolhas para terapia sonodinâmica | |
BR112017008628A2 (pt) | terapia de combinação compreendendo agonistas de ligação a ox40 e inibidores de tigit | |
SV2017005461A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
BR112016006978A2 (pt) | inibidores de tirosina quinase de bruton | |
CL2018000299A1 (es) | Composiciones con potenciadores de impregnacion para el suministro de fármacos. | |
BR112017005693A2 (pt) | método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica. | |
BR112018005777A2 (pt) | anticorpo, polinucleotídeo, vetor de expressão, células hospedeiras, método para produzir um anticorpo de interesse ou um fragmento do mesmo composição farmacêutica, e, uso de pelo menos um anticorpo | |
BR112018077021A2 (pt) | terapias de combinação | |
AR100353A1 (es) | Droga de direccionamiento a glipicano 3 (gpc3) que se administra a un paciente que responde a la terapia con drogas de direccionamiento a gpc3 | |
AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
BR112018008601A2 (pt) | composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer | |
MX2019005435A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
BR112017006113A8 (pt) | usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits. | |
BR112016017897A8 (pt) | uso de composto de carboxamida heterocíclica de diamino no tratamento de câncer relacionado ao axl, composição farmacêutica e combinação | |
BR112018076639A2 (pt) | quimioterapias de combinação | |
BR112017007748A2 (pt) | composição farmacêutica, agente antialérgico, composição alimentar, composição cosmética, uso de um extrato, e, método para prevenir ou tratar uma doença alérgica | |
MX2017004772A (es) | Composiciones y métodos para la administración fisiológica utilizando cannabidiol. | |
BR112018002530A2 (pt) | combinações e usos e tratamentos destas | |
BR112015022846A2 (pt) | uso de um composto para tratar ou prevenir um angioedema mediado pelo receptor b2 da bradicinina e formulação compreendendo o mesmo | |
BR112015019873A2 (pt) | inibidores macrocíclicos da lrrk2 cinase | |
CO2019002245A2 (es) | Combinación de agonistas de fxr | |
CL2018003214A1 (es) | Composiciones cosméticas prebióticas y uso de las composiciones cosméticas prebióticas | |
ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B65X | Notification of requirement for priority examination of patent application | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |